Curi RMB Capital LLC Grows Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Curi RMB Capital LLC boosted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 18.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 84,873 shares of the medical instruments supplier’s stock after buying an additional 13,030 shares during the quarter. Curi RMB Capital LLC’s holdings in Becton, Dickinson and Company were worth $20,463,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Livelsberger Financial Advisory bought a new stake in shares of Becton, Dickinson and Company in the 3rd quarter valued at about $26,000. Ashton Thomas Securities LLC purchased a new position in Becton, Dickinson and Company during the third quarter valued at approximately $33,000. Tompkins Financial Corp raised its stake in Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 46 shares in the last quarter. Sound Income Strategies LLC lifted its holdings in Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 44 shares during the period. Finally, Kennebec Savings Bank bought a new stake in Becton, Dickinson and Company during the 3rd quarter valued at $46,000. Institutional investors own 86.97% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Raymond James decreased their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Stifel Nicolaus increased their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Finally, Evercore ISI raised their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Buy” and an average target price of $283.00.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $231.26 on Thursday. The stock has a 50-day moving average of $236.56 and a two-hundred day moving average of $235.10. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17. The stock has a market cap of $66.84 billion, a P/E ratio of 38.93, a P/E/G ratio of 1.72 and a beta of 0.43. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $249.89.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, beating analysts’ consensus estimates of $3.77 by $0.04. The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. Becton, Dickinson and Company’s revenue for the quarter was up 6.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.42 earnings per share. As a group, research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be given a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 1.80%. The ex-dividend date is Monday, December 9th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s dividend payout ratio is currently 63.97%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.